Pune, India, Aug. 28, 2023 (GLOBE NEWSWIRE) -- The global allergic conjunctivitis market size was USD 2.74 billion in 2022 and it is projected to grow from USD 2.89 billion in 2023 to USD 4.26 billion by 2030, exhibiting a CAGR of 5.7% during the forecast period. Allergic conjunctivitis is a disorder where the eye's conjunctiva inflates due to an allergic reaction resulting from an individual’s interaction with an allergen.
This disease affects a considerable proportion of the global population but is often underdiagnosed and ignored by the patient and the healthcare professional.
Fortune Business Insights™ mentioned this in a report titled “Allergic Conjunctivitis Market, 2023-2030.”
Key Industry Development:
- March 2022: Johnson & Johnson Vision Care, Inc. declared the approval of ACUVUE Theravision with Ketotifen by U.S. FDA.
Request a Free Sample PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/allergic-conjunctivitis-market-100121
Key Takeaways:
- The FDA in the United States has approved etafilcon, a drug-eluting contact lens containing ketotifen, under the brand name ACUVUE Theravision, according to Johnson & Johnson Vision Care, Inc.
- Pataday Once Daily Relief Extra Strength is now widely available at retail locations in the United States, according to Alcon.
- Alaway Preservative Free Antihistamine Eye Drops, the first over-the-counter (OTC) preservative-free formulation eye drop, was introduced by Bausch & Lomb.
- The first brand-new, prescription-only medication for allergic conjunctivitis in the United States in ten years, ZERVIATE (cetirizine ophthalmic solution) 0.24%, was just released, according to Eyevance Pharmaceuticals LLC.
Discover the Leading Players Featured in the Report:
Major players in the allergic conjunctivitis market are Allergan (AbbVie Inc.) (U.S.), Santen Pharmaceutical Co., Ltd. Japan), Bausch & Lomb Incorporated (Canada), Alcon (Switzerland), Novartis AG (Switzerland), Eyevance Pharmaceuticals LLC (U.S.), Sun Pharmaceutical Industries Ltd. India), Ocular Therapeutix, Inc. (U.S.), Eton Pharmaceutical (U.S.)
Report Scope
| Report Coverage | Details |
| Forecast Period | 2023 to 2030 |
| Forecast Period 2023 to 2030 CAGR | 5.7% |
| 2030 Value Projection | USD 4.26 Billion |
| Base Year | 2022 |
| Market Size in 2023 | USD 2.89 Billion |
| Historical Data for | 2019 to 2021 |
| No. of Pages | 140 |
Browse Complete Report Details: https://www.fortunebusinessinsights.com/industry-reports/allergic-conjunctivitis-market-100121
Drivers & Restraints:
Rapid Growth in Number of Ocular Allergens to Drive the Market Growth
The occurrence of ocular allergy has increased intensely over the past few decades due to several factors that comprise rapid industrialization and urbanization coupled with the increase in the number of allergens.
A significant lack of understanding about the various symptoms of eye allergies. Hence patients do not visit ophthalmologists regularly unless there is a major or severe symptomatic condition.
Segmentation:
Mast Cell Stabilizers and Antihistamines Segment to Skyrocket the Growth of New Product
Based on drug class, the market is divided into corticosteroids, antihistamines & mast cell stabilizers, and others.
The antihistamines & mast cell stabilizers segment is expected to expand at a significant CAGR over the projected period, owing to their reputation as the gold standard treatment for ocular energy.
Expensive Treatment Costs of Severe Allergic Conjunctivitis to Permit the Segment’s Dominance
On the basis of disease type, the market is bifurcated into mild and severe.
The severe allergic conjunctivitis segment leads with the largest share for multiple reasons. Treating this form of conjunctivitis necessitates, the usage of advanced and strong prescription pharmaceuticals.
Hospital Pharmacies to Dominate Due to High Demand for These Institutions for Medical Examinations
According to the distribution channel, the market is fragmented into drug stores & retail pharmacies, hospital pharmacies, and online pharmacies. The hospital pharmacies segment is expected to accredit for the largest market share during the projected period. The dominance of the segment is due to the increasing demand for institutions with trained medical professionals.
By Drug Class
- Antihistamines & Mast Cell Stabilizers
- Corticosteroids
- Others
By Disease Type
- Mild Allergic Conjunctivitis
- Severe Allergic Conjunctivitis
By Distribution Channel
- Hospital Pharmacies
- Drug Stores & Retail Pharmacies
- Online Pharmacies
By Region
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East & Africa
Quick Buy - Allergic Conjunctivitis Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100121
Report Coverage:
- Major growth drivers, restraining factors, opportunities, and potential challenges for the market.
- Comprehensive insights into regional developments.
- List of major industry players.
- Key strategies adopted by the market players.
- Latest industry developments such as product launches, partnerships, mergers, and acquisitions.
Regional Insights:
North America to Lead the Market Owing to Surging Occurrence of Ocular Allergies
North America held the largest share in 2022 and is predicted to continue to dominate the global allergic conjunctivitis market share during the projected period. The region’s growth is due to the widespread awareness of ocular allergies, the vital occurrence of this disease, and the presence of key players resulting in the launches of advanced drugs.
Asia Pacific market is anticipated to record the highest CAGR owing to surging awareness, considerable improvements in healthcare expenditure, and a rising occurrence of ocular allergies in the region.
Competitive Landscape:
Healthy Product Portfolio of Prominent Players to Ensure Apex Position
The market is dominant owing to the presence of major players of different sizes, with a number of players targeting the genetic drug space for the treatment of eye allergies. Moreover, companies such as Alembic Pharmaceuticals Limited and Sun Pharmaceuticals are growing their presence in the global market by focusing on product approvals and introducing generic versions of existing drugs.
FAQ’s
How big is the Allergic Conjunctivitis Market?
Allergic Conjunctivitis Market size was USD 2.89 Billion in 2023.
How fast is the Allergic Conjunctivitis Market growing?
The Allergic Conjunctivitis Market will exhibit a CAGR of 5.7% during the forecast period, 2019-2030
Related Reports:
Conjunctivitis Treatment Market Share, Size, Trends and Forecast 2020-2027
Dry Eye Syndrome Market Size, Share, Trends, Growth | Global Forecast Report 2030
Ophthalmic Disease Therapeutics Market Size, Share| Global Forecast Report 2030
Non-steroidal Anti-Inflammatory Drugs (NSAIDs) Market Trends, Growth | Global Forecast Report 2027
About Us:
Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in. Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.
Contact Us:
Fortune Business Insights Pvt. Ltd.
9th Floor, Icon Tower, Baner - Mahalunge Road,
Baner, Pune-411045,
Maharashtra, India.
Phone:
US:+1 424 253 0390
UK: +44 2071 939123
APAC: +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Attachment
